SUBSCRIBE
SUBSCRIBE

Genprex, Inc.

NEWS
Courtesy Getty Images
Drug Development
CRISPR/ViaCyte and Genprex Vie for First Diabetes Gene Therapy
Partners CRISPR and ViaCyte (Vertex), and Genprex are pioneers in the quest to develop a gene therapy for Type 1 diabetes.
March 10, 2023
 · 
3 min read
 · 
Jia Jie Chen
Drug Development
Clinical Catch-Up: Covaxin, Celyad Hold, CRISPR’s Next Step
The biopharma industry ended February and began March with plenty of clinical trial news. BioSpace shares the highlights.
March 4, 2022
 · 
8 min read
 · 
Mark Terry
Drug Development
Clinical Catch-Up: November 30-December 4
It was a moderately busy week for clinical trial news, with some important reports coming out about COVID-19 vaccines. Here’s a look.
December 4, 2020
 · 
8 min read
 · 
Mark Terry
Deals
A Look at the Year’s Most and Least Successful Biotech IPOs
Although the size of the IPO is one aspect of determining the success of a company’s public launch, it’s not the only metric. How the stock does in the ensuing months is a very important consideration.
December 19, 2018
 · 
4 min read
 · 
Mark Terry
JOBS
IN THE PRESS
Press Releases
Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System
February 20, 2025
 · 
8 min read
Press Releases
Genprex Provides Update on Diabetes Gene Therapy Program
February 18, 2025
 · 
10 min read
Press Releases
Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer
February 14, 2025
 · 
7 min read
Press Releases
Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
January 23, 2025
 · 
8 min read
Press Releases
Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference
January 6, 2025
 · 
5 min read
Press Releases
Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer
December 16, 2024
 · 
9 min read
Press Releases
Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting
November 6, 2024
 · 
8 min read
Press Releases
Genprex to Participate in 2024 BIO Europe Conference
October 31, 2024
 · 
5 min read
Press Releases
Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma
October 28, 2024
 · 
7 min read
Press Releases
Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive
October 25, 2024
 · 
9 min read
Load More